Business
TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”
DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences, which seeks to transform
About this update from Trisalus Life Sciences, Inc.
[{"type":"text","content":" DENVER--(BUSINESS WIRE)--\n\nTriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences, which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that company researchers received two JVIR Top Paper Awards for a recent publication, including the JVIR Editor’s Award for Distinguished Laboratory Investigation and the JVIR People’s Choice Award for Most Downloaded Articles. These awards will be presented at the 2025 Society for Interventional Radiology meeting in Nashville TN.\n\nThis peer-reviewed study, titled “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model” highlighted the superior performance of the TriNav Infusion System in delivering Glass Microspheres into liver tumors when compared to delivery with a traditional microcatheter. The model used a transgenically modified porcine with therapeutic delivery quantified using a machine learning algorithm which documented tumor penetration at a millimeter scale. The study was published in the Journal of Vascular and Interventional Radiology.\n\nKey Study Findings:\n\n\nIn lobar infusions TriNav increased tumor penetration by 117% (p=0.004)\n\n\nIn selective infusions TriNav increased tumor penetration by 39% (p=0.032)\n\n\nLobar infusions using a TriNav had tumor penetration that was statistically equivalent to selective delivery using a traditional MC (p=0.497)\n\n\n2024 JVIR Top Paper Awards Received by TriSalus:\n\n\n2023 JVIR EDITOR’S AWARD FOR DISTINGUISHED LABORATORY INVESTIGATION. Winning manuscripts are selected after a rigorous review of all JVIR articles published in the preceding year. The chosen articles represent research that may substantially impact the Interventional Radiology community at present or in the future\n\n\n2024 PEOPLE’S CHOICE AWARDS – MOST DOWNLOADED ARTICLES: The People’s Choice Award recognizes articles that garner the most readership interest, measured by the number of downloads\n\n\nThese findings add to the growing body of clinical and real-world evidence supporting PEDD's ability to improve the delivery of therapeutic agents for patients with primary and metastatic liver cancers...